



Updated schedule for change of share unit and reverse share split

July 5, 2018 – GNI Group would like to communicate the schedule for administrative procedures disclosures regarding the change of the Company's share unit and reverse share split effective as of July 1, 2018.

1. Notice regarding the number of allotted shares after the reverse share split and information regarding change of share unit: disclosure in late July
2. Notice regarding disposal of any fractions of less than one share arising from the reverse share split: disclosure in late August *
3. Payment period for proceeds to the shareholder who has fractional shares as a result of disposal: to be initiated in late August *

* All fractions of less than one share arising from the reverse share split shall be disposed and the proceeds shall be paid to the shareholders of those fractions in proportion to the ratio of their fractions. Information will be disclosed concerning the number of fractional shares as well as allotted shares referenced in notice 1. above, if applicable.

Dr. Ying Luo, GNI Group's CEO, said: "We truly appreciated the support of our shareholders in approving the consolidation of shares at the 17th Ordinary General Meeting of Shareholders. As stated at that time, if the Company's stock price moves significantly out of the TSE's recommended trading range, we will again seek shareholder approval to make appropriate adjustments as necessary. I remain confident the fundamentals of the Company are steadily improving, with GNI's management team focused on its commitment to increase corporate value and achieve sustainable growth. We are on track to successfully implement our sales strategy, manufacture expansion, and R&D progress in both China and the US. Further information on such progress will be disclosed on a timely basis as appropriate."

About GNI Group Ltd.

GNI Group Ltd. is a multinational pharmaceutical company listed on the Tokyo Stock Exchange Mothers Market, Code 2160. The Group is headquartered in Tokyo, with primary business units of pharmaceuticals and medical devices with subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information about GNI Group Ltd., please visit www.gnipharma.com.

For further inquiries

+81 (03) 6214-3600

Email: infojapan@gnipharma.com

This press release contains "forward-looking" statements, including statements related to the Group's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to," "will" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause the Group's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. The Group does not undertake any obligation to update forward-looking statements.